A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Bimekizumab

Sponsor

UCB Biopharma SRL